Pemetrexed Market to Garner US$ 2347.6 Mn Threshold By 2026 – Coherent Market Insights
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Global Pemetrexed Market, by Strength (100 mg and 500 mg), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 2,062.5 Mn in 2017, and is projected to exhibit a CAGR of 1.3% during the forecast period (2018–2026), as highlighted in a new report published by Coherent Market Insights.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2458
Approval and launch of affordable generics of Pemetrexed in the market is expected to increase its adoption rate and drive the global pemetrexed market growth. Alimta is a patented drug of Eli Lilly and Company, it has vitamin regimen patent in the U.S. and Europe up to 2021 and pediatric exclusivity in the U.S. up to 2022.
However, the patent for compound of Alimta expired in the U.S. in January 2017, and expired in major European countries and Japan in December 2015. Hence, key players in the market have developed and gained approval for generic versions of Alimta in key regions. For instance, in 2017, Eagle Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for its diluted version of Eli Lilly and Co’s blockbuster cancer drug Alimta.
Launch of generic versions of Pemetrexed is expected to increase the affordability of drugs as generic drugs are cost effective. However, this is projected to affect the revenue to Eli Lilly and Company’s branded drug during the forecast period.
However, Eli Lilly and Company is focused on expanding the indication of Alimta (Pemetrexed) which is expected to support the global Pemetrexed market growth.
For instance, in 2012, Alimta received the FDA approval as maintenance therapy for locally advanced or metastatic NSCLC, following initial ALIMTA-plus-cisplatin treatment for locally advanced or metastatic nonsquamous NSCLC. In 2018, ALIMTA received FDA approval for an additional indication for the combination with carboplatin plus pembrolizumab as first-line treatment for metastatic nonsquamous NSCLC, irrespective of PD-L1 expression status.
Browse 18 Market Data Tables and 20 Figures spread through 130 Pages and in-depth TOC on Global Pemetrexed Market, by Strength (100 mg and 500 mg), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026
To know the latest trends and insights prevalent in the Pemetrexed market Press Release, click the link below: https://bit.ly/34b1aBF
Alimta is a patented drug of Eli Lilly and Company, hence Eli Lilly and Company is delicately working to prevent the launch of generic version of Alimta in key region such as U.S. from where Alimta generates about 50% of its revenue.
For instance, in June 2018, Eli Lilly and Company got a favorable result from the U.S. District Court and prevented Hospira Inc. and India’s Dr. Reddy’s Laboratories from launching generic version of Alimta until the patent expires in 2022.
Key Takeaways of the Pemetrexed Market:
- The global Pemetrexed market is expected to exhibit a CAGR of 1.3% during the forecast period (2018 – 2026) owing approval and launch of affordable generics of pemetrexed in the market, which is expected to increase its adoption.
- North America is expected to account for major market share in global pemetrexed market owing to high prevalence of non-small cell lung cancer and its high treatment rate.
- Launch of generic version of Pemetrexed in Germany by STADAPHARM GmbH in July 2018, is expected to increase the affordability of the drug in the region. However, it is likely to affect the revenue of Eli Lilly and Company’s branded drug, Alimta.
- Eli Lilly and Company, the patent holder of Alimta, is dedicated to preventing the launch of generic versions of Alimta in key regions to maintain its position and market share.
- Major players operating in the global Pemetrexed market are Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others.
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2458
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire